$nbsp;

grafika

Compilation

Comparison of currently available vaccines:

  • Pfizer / BioNTech vaccine (trade name Comirnaty)
  • Moderna vaccine (trade name COVID-19 Vaccine Moderna)

Pfizer / BioNTech

logo

Moderna

logo

Characteristics

Pfizer / BioNTech
An American-German vaccine based on mRNA technology delivers to our cells the "instruction" to produce the S protein S (Spike) of the SARS-CoV-2 virus. The next step is the production of immune antibodies directed against the virus, followed by degradation of the mRNA.

Moderna
A US vaccine based on lipid envelope-stabilised mRNA technology that encodes the SARS-CoV-2 virus S-protein, enabling the generation of acquired immunity, with the mRNA degraded in the interim.

Pfizer / BioNTech

mRNA

Modern

mRNA

Submission

Pfizer / BioNTech
The vaccine is administered intramuscularly in two doses 21 days apart.

Moderna
The vaccine is administered intramuscularly in two doses 28 days apart.

Testing

Pfizer / BioNTech

  • A Phase I/II clinical trial that enrolled 456 subjects. The study evaluated four vaccine variants BNT162a1, BNT162b1, BNT162b2 and BNT162c2, which were administered at doses of 1 µg, 10 µg, 20 µg and 30 µg. The best results were obtained with the 30 µg dose.
  • .
  • The phase I/II/III clinical trial was divided into two phases. In the first stage, two variants of the vaccine BNT162b1 and BNT162b2 were compared in a regimen of two doses of 10 µg, 20 µg or 30 µg administered 21 days apart in a population of 195 subjects. The 30 µg dose of BNT162b2 vaccine was selected for the second phase of the study.
  • .
  • A phase II/III clinical trial evaluating the safety, efficacy and immunogenicity of the BNT162b2 vaccine variant compared to placebo in a population of 43,448 subjects. The 62 clinical trial sites were located in Germany and the United States.

Modern

  • The Phase I clinical study was initiated by testing the safety, efficacy and immunogenicity of three vaccine doses of 25 μg, 100 μg or 250 μg on a population of 45 subjects. Results showed promise as immunogenicity was confirmed. In a continuation of the clinical trial on a population of 34 subjects, the 100 μg vaccine variant was selected. In this additional phase, the durability of the immune response was evaluated up to 90 days after the second dose of the vaccine (119 days after the first dose). The results confirmed the researchers' assumptions: the highest antibody titres were observed after the second dose of the vaccine, which gradually decreased over time but were still high compared to control subjects.
  • The Phase II clinical trial was conducted from April 2020 in Wuhan, China on a population of 508 volunteers. The populations were divided into three groups: 126 subjects received a placebo, 129 subjects received the vaccine at a dose of 50*10^9 molecules per mL, 253 subjects received the vaccine at a dose of 100*10^9 molecules per mL. The results confirmed antibody production in the majority of people who received the vaccine after the first dose.
  • A phase III clinical trial to determine the safety, efficacy and immunogenicity of two doses of mRNA-1273 vaccine at 100 μg compared to placebo was conducted on a population of 30,000 people.

Efficacy

Pfizer / BioNTech
Results of the clinical trial were published on 10 December 2020. The efficacy of the vaccine was determined to be 95%.

Modern
The results of the clinical trial were made public on 15 November 2020, setting the vaccine efficacy at 94.5%.

Pfizer / BioNTech

95%

Moderna

94.5%

 

Gaining full immunity

Pfizer / BioNTech
Gaining full immunity occurs 7 days after the second dose.

Moderna
Full immunity is achieved 14 days after the second dose.

Pfizer / BioNTech

7 days

Moderna

14 days

Temperature

Pfizer / BioNTech
The vaccine should be stored at approximately -70°C.

Moderna
Store the vaccine at a temperature of approximately -20°C.

Pfizer / BioNTech

-70°C

Modern

-20°C

 

Stability after thawing

Pfizer / BioNTech
The vaccine is stable for 5 days at 2°C - 8°C .

Moderna
The vaccine is stable for 30 days at 2°C - 8°C .

Pfizer / BioNTech

5 days

Moderna

30 days

Price

It is difficult to set a precise price for 1 dose of vaccine. Its value is influenced mainly by the number of ordered vaccines and the time when the order is placed. It is possible to assume average prices for particular doses of vaccines. 

Pfizer / BioNTech
Price of one dose of vaccine approximately $20.

Modern
Price of one dose of vaccine approximately $33.

Pfizer / BioNTech

$20

Moderna

$33

Registration

Pfizer / BioNTech
Based on the data received, the BNT162b2 variant of the COVID-19 vaccine was conditionally authorised for marketing and use in the European Union on 21 December 2020 under the trade name Comirnaty. The official product characteristics of Comirnaty in Polish are available at the link:
https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_pl.pdf

Moderna
Based on the results, the mRNA-1273 vaccine has been conditionally authorised for marketing and use in the European Union under the trade name COVID-19 Vaccine Moderna. The official product specification of COVID-19 Vaccine Moderna in Polish is available at the link:
https://ec.europa.eu/health/documents/community-register/2021/20210106150575/anx_150575_pl.pdf

Material was prepared by: Andrzej Jamkowy, Magdalena Bednarek

article prev
Poprzedni

This website uses cookies. Check out our privacy policy oraz cookie policy to learn more.

Accept